Tumor necrosis factor inhibitors in patients with Takayasu arteritis: Experience from a referral center with long‐term followup
Objective To report a single‐center experience with the use of tumor necrosis factor (TNF) inhibitors in patients with Takayasu arteritis (TA). Methods We retrospectively studied a cohort of patients with refractory TA evaluated at our institution and treated with TNF inhibitors. American College of...
Gespeichert in:
| Veröffentlicht in: | Arthritis care & research (2010) 2012-07, Vol.64 (7), p.1079-1083 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1083 |
|---|---|
| container_issue | 7 |
| container_start_page | 1079 |
| container_title | Arthritis care & research (2010) |
| container_volume | 64 |
| creator | Schmidt, Jean Kermani, Tanaz A. Bacani, A. Kirstin Crowson, Cynthia S. Matteson, Eric L. Warrington, Kenneth J. |
| description | Objective
To report a single‐center experience with the use of tumor necrosis factor (TNF) inhibitors in patients with Takayasu arteritis (TA).
Methods
We retrospectively studied a cohort of patients with refractory TA evaluated at our institution and treated with TNF inhibitors. American College of Rheumatology criteria for TA were used for inclusion. Disease activity was assessed according to the National Institutes of Health criteria.
Results
We included 20 patients (19 women, 17 white) with a mean ± SD age of 33 ± 10.2 years and a median disease duration of 15.9 months (interquartile range [IRQ] 2–32.7 months) prior to the use of TNF inhibitors. Before the use of TNF inhibitors, all 20 patients received prednisone. Other medication use included methotrexate (18 patients), azathioprine (5 patients), mycophenolate mofetil (3 patients), and cyclophosphamide (3 patients). Seventeen patients (85%) received infliximab, 2 patients (10%) received adalimumab, and 1 patient (5%) received etanercept. The median duration of treatment with TNF inhibitors was 23.0 months (IQR 8.7–38.9 months). Treatment with TNF inhibitors resulted in disease remission in 18 (90%) of 20 patients and sustained remission in 10 patients (50%). Ten (83%) of 12 patients were able to taper prednisone below 10 mg and 7 patients discontinued prednisone. However, 6 of the 18 patients achieving remission experienced relapse while receiving TNF inhibitors. Eleven patients (55%) discontinued TNF inhibitors for the following reasons: relapse, persistently active disease, lack of corticosteroid‐sparing effect, adverse effects (4 patients), and other reasons (4 patients).
Conclusion
In this study, treatment with TNF inhibitors induced remission, including sustained remission in patients with refractory TA. However, 33% of patients experienced disease relapse while receiving TNF inhibitors and 20% discontinued treatment because of adverse events. |
| doi_str_mv | 10.1002/acr.21636 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1022841759</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1022841759</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3256-5e6c5688cc2dcbea1b6f75d9bc9a8b4470c40f49dcc4d4bc546fae207de6a7a53</originalsourceid><addsrcrecordid>eNp1kMtKxDAUhoMozqCz8AUkS12MNmmStu6GwRsMCDKCu3Kanmq0N5OWcXb6Bj6jT2K0ozuzyX_gOz-cj5ADFpywIOCnoO0JZypUW2TMmWRToWS8_ZfF_YhMnHsK_At5HIfJLhlx7qNI2Ji8L_uqsbRGbRtnHC1Ad3429aPJjE_OR9pCZ7DuHF2Z7pEu4RnW4HoKtkNrOuPO6Plr6yPWGmlhm4oCtVigtVBS7TfRDqtlUz98vn34uaJFU5bNqm_3yU4BpcPJ5t8jdxfny_nVdHFzeT2fLaY65FJNJSotVRxrzXOdIbBMFZHMk0wnEGdCRIEWQSGSXGuRi0xLoQpAHkQ5KohAhnvkaOhtbfPSo-vSyjiNZQk1Nr1LWcC9ExbJxKPHA_otxflL0taaCuzaQ-m39NRLT3-ke_ZwU9tnFeZ_5K9iD5wOwMqUuP6_KZ3Nb4fKL5v4j_0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1022841759</pqid></control><display><type>article</type><title>Tumor necrosis factor inhibitors in patients with Takayasu arteritis: Experience from a referral center with long‐term followup</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Schmidt, Jean ; Kermani, Tanaz A. ; Bacani, A. Kirstin ; Crowson, Cynthia S. ; Matteson, Eric L. ; Warrington, Kenneth J.</creator><creatorcontrib>Schmidt, Jean ; Kermani, Tanaz A. ; Bacani, A. Kirstin ; Crowson, Cynthia S. ; Matteson, Eric L. ; Warrington, Kenneth J.</creatorcontrib><description>Objective
To report a single‐center experience with the use of tumor necrosis factor (TNF) inhibitors in patients with Takayasu arteritis (TA).
Methods
We retrospectively studied a cohort of patients with refractory TA evaluated at our institution and treated with TNF inhibitors. American College of Rheumatology criteria for TA were used for inclusion. Disease activity was assessed according to the National Institutes of Health criteria.
Results
We included 20 patients (19 women, 17 white) with a mean ± SD age of 33 ± 10.2 years and a median disease duration of 15.9 months (interquartile range [IRQ] 2–32.7 months) prior to the use of TNF inhibitors. Before the use of TNF inhibitors, all 20 patients received prednisone. Other medication use included methotrexate (18 patients), azathioprine (5 patients), mycophenolate mofetil (3 patients), and cyclophosphamide (3 patients). Seventeen patients (85%) received infliximab, 2 patients (10%) received adalimumab, and 1 patient (5%) received etanercept. The median duration of treatment with TNF inhibitors was 23.0 months (IQR 8.7–38.9 months). Treatment with TNF inhibitors resulted in disease remission in 18 (90%) of 20 patients and sustained remission in 10 patients (50%). Ten (83%) of 12 patients were able to taper prednisone below 10 mg and 7 patients discontinued prednisone. However, 6 of the 18 patients achieving remission experienced relapse while receiving TNF inhibitors. Eleven patients (55%) discontinued TNF inhibitors for the following reasons: relapse, persistently active disease, lack of corticosteroid‐sparing effect, adverse effects (4 patients), and other reasons (4 patients).
Conclusion
In this study, treatment with TNF inhibitors induced remission, including sustained remission in patients with refractory TA. However, 33% of patients experienced disease relapse while receiving TNF inhibitors and 20% discontinued treatment because of adverse events.</description><identifier>ISSN: 2151-464X</identifier><identifier>EISSN: 2151-4658</identifier><identifier>DOI: 10.1002/acr.21636</identifier><identifier>PMID: 22328491</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>Adalimumab ; Adult ; Anti-Inflammatory Agents - therapeutic use ; Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Humanized - adverse effects ; Antibodies, Monoclonal, Humanized - therapeutic use ; Drug Therapy, Combination ; Etanercept ; Female ; Follow-Up Studies ; Humans ; Immunoglobulin G - adverse effects ; Immunoglobulin G - therapeutic use ; Infliximab ; Longitudinal Studies ; Male ; Prednisone - therapeutic use ; Receptors, Tumor Necrosis Factor - therapeutic use ; Recurrence ; Remission Induction ; Retrospective Studies ; Takayasu Arteritis - drug therapy ; Treatment Outcome ; Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><ispartof>Arthritis care & research (2010), 2012-07, Vol.64 (7), p.1079-1083</ispartof><rights>Copyright © 2012 by the American College of Rheumatology</rights><rights>Copyright © 2012 by the American College of Rheumatology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3256-5e6c5688cc2dcbea1b6f75d9bc9a8b4470c40f49dcc4d4bc546fae207de6a7a53</citedby><cites>FETCH-LOGICAL-c3256-5e6c5688cc2dcbea1b6f75d9bc9a8b4470c40f49dcc4d4bc546fae207de6a7a53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Facr.21636$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Facr.21636$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22328491$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schmidt, Jean</creatorcontrib><creatorcontrib>Kermani, Tanaz A.</creatorcontrib><creatorcontrib>Bacani, A. Kirstin</creatorcontrib><creatorcontrib>Crowson, Cynthia S.</creatorcontrib><creatorcontrib>Matteson, Eric L.</creatorcontrib><creatorcontrib>Warrington, Kenneth J.</creatorcontrib><title>Tumor necrosis factor inhibitors in patients with Takayasu arteritis: Experience from a referral center with long‐term followup</title><title>Arthritis care & research (2010)</title><addtitle>Arthritis Care Res (Hoboken)</addtitle><description>Objective
To report a single‐center experience with the use of tumor necrosis factor (TNF) inhibitors in patients with Takayasu arteritis (TA).
Methods
We retrospectively studied a cohort of patients with refractory TA evaluated at our institution and treated with TNF inhibitors. American College of Rheumatology criteria for TA were used for inclusion. Disease activity was assessed according to the National Institutes of Health criteria.
Results
We included 20 patients (19 women, 17 white) with a mean ± SD age of 33 ± 10.2 years and a median disease duration of 15.9 months (interquartile range [IRQ] 2–32.7 months) prior to the use of TNF inhibitors. Before the use of TNF inhibitors, all 20 patients received prednisone. Other medication use included methotrexate (18 patients), azathioprine (5 patients), mycophenolate mofetil (3 patients), and cyclophosphamide (3 patients). Seventeen patients (85%) received infliximab, 2 patients (10%) received adalimumab, and 1 patient (5%) received etanercept. The median duration of treatment with TNF inhibitors was 23.0 months (IQR 8.7–38.9 months). Treatment with TNF inhibitors resulted in disease remission in 18 (90%) of 20 patients and sustained remission in 10 patients (50%). Ten (83%) of 12 patients were able to taper prednisone below 10 mg and 7 patients discontinued prednisone. However, 6 of the 18 patients achieving remission experienced relapse while receiving TNF inhibitors. Eleven patients (55%) discontinued TNF inhibitors for the following reasons: relapse, persistently active disease, lack of corticosteroid‐sparing effect, adverse effects (4 patients), and other reasons (4 patients).
Conclusion
In this study, treatment with TNF inhibitors induced remission, including sustained remission in patients with refractory TA. However, 33% of patients experienced disease relapse while receiving TNF inhibitors and 20% discontinued treatment because of adverse events.</description><subject>Adalimumab</subject><subject>Adult</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized - adverse effects</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Drug Therapy, Combination</subject><subject>Etanercept</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Immunoglobulin G - adverse effects</subject><subject>Immunoglobulin G - therapeutic use</subject><subject>Infliximab</subject><subject>Longitudinal Studies</subject><subject>Male</subject><subject>Prednisone - therapeutic use</subject><subject>Receptors, Tumor Necrosis Factor - therapeutic use</subject><subject>Recurrence</subject><subject>Remission Induction</subject><subject>Retrospective Studies</subject><subject>Takayasu Arteritis - drug therapy</subject><subject>Treatment Outcome</subject><subject>Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><issn>2151-464X</issn><issn>2151-4658</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kMtKxDAUhoMozqCz8AUkS12MNmmStu6GwRsMCDKCu3Kanmq0N5OWcXb6Bj6jT2K0ozuzyX_gOz-cj5ADFpywIOCnoO0JZypUW2TMmWRToWS8_ZfF_YhMnHsK_At5HIfJLhlx7qNI2Ji8L_uqsbRGbRtnHC1Ad3429aPJjE_OR9pCZ7DuHF2Z7pEu4RnW4HoKtkNrOuPO6Plr6yPWGmlhm4oCtVigtVBS7TfRDqtlUz98vn34uaJFU5bNqm_3yU4BpcPJ5t8jdxfny_nVdHFzeT2fLaY65FJNJSotVRxrzXOdIbBMFZHMk0wnEGdCRIEWQSGSXGuRi0xLoQpAHkQ5KohAhnvkaOhtbfPSo-vSyjiNZQk1Nr1LWcC9ExbJxKPHA_otxflL0taaCuzaQ-m39NRLT3-ke_ZwU9tnFeZ_5K9iD5wOwMqUuP6_KZ3Nb4fKL5v4j_0</recordid><startdate>201207</startdate><enddate>201207</enddate><creator>Schmidt, Jean</creator><creator>Kermani, Tanaz A.</creator><creator>Bacani, A. Kirstin</creator><creator>Crowson, Cynthia S.</creator><creator>Matteson, Eric L.</creator><creator>Warrington, Kenneth J.</creator><general>John Wiley & Sons, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201207</creationdate><title>Tumor necrosis factor inhibitors in patients with Takayasu arteritis: Experience from a referral center with long‐term followup</title><author>Schmidt, Jean ; Kermani, Tanaz A. ; Bacani, A. Kirstin ; Crowson, Cynthia S. ; Matteson, Eric L. ; Warrington, Kenneth J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3256-5e6c5688cc2dcbea1b6f75d9bc9a8b4470c40f49dcc4d4bc546fae207de6a7a53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adalimumab</topic><topic>Adult</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized - adverse effects</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Drug Therapy, Combination</topic><topic>Etanercept</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Immunoglobulin G - adverse effects</topic><topic>Immunoglobulin G - therapeutic use</topic><topic>Infliximab</topic><topic>Longitudinal Studies</topic><topic>Male</topic><topic>Prednisone - therapeutic use</topic><topic>Receptors, Tumor Necrosis Factor - therapeutic use</topic><topic>Recurrence</topic><topic>Remission Induction</topic><topic>Retrospective Studies</topic><topic>Takayasu Arteritis - drug therapy</topic><topic>Treatment Outcome</topic><topic>Tumor Necrosis Factor-alpha - antagonists & inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schmidt, Jean</creatorcontrib><creatorcontrib>Kermani, Tanaz A.</creatorcontrib><creatorcontrib>Bacani, A. Kirstin</creatorcontrib><creatorcontrib>Crowson, Cynthia S.</creatorcontrib><creatorcontrib>Matteson, Eric L.</creatorcontrib><creatorcontrib>Warrington, Kenneth J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Arthritis care & research (2010)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schmidt, Jean</au><au>Kermani, Tanaz A.</au><au>Bacani, A. Kirstin</au><au>Crowson, Cynthia S.</au><au>Matteson, Eric L.</au><au>Warrington, Kenneth J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tumor necrosis factor inhibitors in patients with Takayasu arteritis: Experience from a referral center with long‐term followup</atitle><jtitle>Arthritis care & research (2010)</jtitle><addtitle>Arthritis Care Res (Hoboken)</addtitle><date>2012-07</date><risdate>2012</risdate><volume>64</volume><issue>7</issue><spage>1079</spage><epage>1083</epage><pages>1079-1083</pages><issn>2151-464X</issn><eissn>2151-4658</eissn><abstract>Objective
To report a single‐center experience with the use of tumor necrosis factor (TNF) inhibitors in patients with Takayasu arteritis (TA).
Methods
We retrospectively studied a cohort of patients with refractory TA evaluated at our institution and treated with TNF inhibitors. American College of Rheumatology criteria for TA were used for inclusion. Disease activity was assessed according to the National Institutes of Health criteria.
Results
We included 20 patients (19 women, 17 white) with a mean ± SD age of 33 ± 10.2 years and a median disease duration of 15.9 months (interquartile range [IRQ] 2–32.7 months) prior to the use of TNF inhibitors. Before the use of TNF inhibitors, all 20 patients received prednisone. Other medication use included methotrexate (18 patients), azathioprine (5 patients), mycophenolate mofetil (3 patients), and cyclophosphamide (3 patients). Seventeen patients (85%) received infliximab, 2 patients (10%) received adalimumab, and 1 patient (5%) received etanercept. The median duration of treatment with TNF inhibitors was 23.0 months (IQR 8.7–38.9 months). Treatment with TNF inhibitors resulted in disease remission in 18 (90%) of 20 patients and sustained remission in 10 patients (50%). Ten (83%) of 12 patients were able to taper prednisone below 10 mg and 7 patients discontinued prednisone. However, 6 of the 18 patients achieving remission experienced relapse while receiving TNF inhibitors. Eleven patients (55%) discontinued TNF inhibitors for the following reasons: relapse, persistently active disease, lack of corticosteroid‐sparing effect, adverse effects (4 patients), and other reasons (4 patients).
Conclusion
In this study, treatment with TNF inhibitors induced remission, including sustained remission in patients with refractory TA. However, 33% of patients experienced disease relapse while receiving TNF inhibitors and 20% discontinued treatment because of adverse events.</abstract><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>22328491</pmid><doi>10.1002/acr.21636</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2151-464X |
| ispartof | Arthritis care & research (2010), 2012-07, Vol.64 (7), p.1079-1083 |
| issn | 2151-464X 2151-4658 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1022841759 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adalimumab Adult Anti-Inflammatory Agents - therapeutic use Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Drug Therapy, Combination Etanercept Female Follow-Up Studies Humans Immunoglobulin G - adverse effects Immunoglobulin G - therapeutic use Infliximab Longitudinal Studies Male Prednisone - therapeutic use Receptors, Tumor Necrosis Factor - therapeutic use Recurrence Remission Induction Retrospective Studies Takayasu Arteritis - drug therapy Treatment Outcome Tumor Necrosis Factor-alpha - antagonists & inhibitors |
| title | Tumor necrosis factor inhibitors in patients with Takayasu arteritis: Experience from a referral center with long‐term followup |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T19%3A25%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tumor%20necrosis%20factor%20inhibitors%20in%20patients%20with%20Takayasu%20arteritis:%20Experience%20from%20a%20referral%20center%20with%20long%E2%80%90term%20followup&rft.jtitle=Arthritis%20care%20&%20research%20(2010)&rft.au=Schmidt,%20Jean&rft.date=2012-07&rft.volume=64&rft.issue=7&rft.spage=1079&rft.epage=1083&rft.pages=1079-1083&rft.issn=2151-464X&rft.eissn=2151-4658&rft_id=info:doi/10.1002/acr.21636&rft_dat=%3Cproquest_cross%3E1022841759%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1022841759&rft_id=info:pmid/22328491&rfr_iscdi=true |